FDA approves belzutifan with lenvatinib for advanced clear cell RCC after PD-1/PD-L1 inhibitor failure. Review LITESPARK-011 data and nursing takeaways.
News|Articles|August 12, 2026
Tudriqev Melanoma Approval: Essential Oncolytic Guide for Oncology Nurses
Author(s)By ONN Staff
Fact checked by: Alex Biese
FDA approves Tudriqev-nivolumab for advanced melanoma. Learn key clinical trial data, dosing math, and safety rules for oncology nursing teams.
Advertisement
Advertisement
The US Food and Drug Administration (FDA) has granted accelerated approval to vusolimogene oderparepvec-wtpg (Tudriqev; Replimune, Inc.), a genetically modified oncolytic viral therapy, in combination with nivolumab. This novel regimen is indicated for adult patients with unresectable advanced cutaneous melanoma who experienced disease progression on a prior programmed death receptor-1 (PD-1)-blocking antibody-based regimen.
Related to this article
FDA approves lirafugratinib (Lyrfigtu) for FGFR2+ cholangiocarcinoma. Review REFOCUS trial data, 70 mg daily dosing, and nursing safety guidelines.
FDA approves lutetium lu 177 dotatate (Bravnetsa) as bioequivalent to Lutathera for GEP-NETs. Review key nursing takeaways and safety guidelines.
FDA approves imlunestrant plus abemaciclib for ESR1-mutated, ER-positive, HER2-negative advanced or metastatic breast cancer after endocrine therapy.
FDA approves sNDA for taletrectinib (Ibtrozi) in ROS1+ NSCLC with updated DOR of nearly 50 months.
The FDA expands accelerated approval for sevabertinib to frontline HER2-mutant NSCLC, highlighting a need for vigilant nursing management of diarrhea.
FDA approves cabozantinib capsules for RCC, HCC, and epNET. Review key dosing conversions and safety guidelines for oncology nursing practice.
The FDA expands accelerated approval for sevabertinib to frontline HER2-mutant NSCLC, highlighting a need for vigilant nursing management of diarrhea.
Advertisement
Advertisement